Genomic Analysis Yields ‘Hypothesis Generating’ Data in Bladder Cancer Subtype
February 26th 2023An expert from Chase Comprehensive Cancer Center discusses how findings from a genomic analysis of the phase 2 BLASST-1 trial may identify biomarkers of response and resistance to nivolumab/chemotherapy in muscle-invasive bladder cancer.
Treatment Options After Progression on Frontline Maintenance Therapy
May 13th 2022Petros Grivas, MD, PhD, revisits the patient profile and invites panel members to share recommended treatment options for patients with or without FGFR mutations, who progress after chemotherapy and maintenance avelumab.